Jacques Raubenheimer

19PUBLICATIONS

61CO-AUTHORS

Gene and molecular therapyPeople with disabilityHypersonic propulsion and hypersonic aerothermodynamicsRegenerative medicine (incl. stem cells)Toxicology (incl. clinical toxicology)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|May 15, 2026

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

|Aug 14, 2025

Toward Normalizing Inclusive Design by Uncovering Patient Experiences of a Web Portal in a Dental Hospital: Mixed Methods Study.

Adeola Bamgboje-Ayodele, Jacques Raubenheimer, Anna Paonne

|Jul 16, 2025

Treatment Persistence in Rheumatoid Arthritis Before and After Etanercept Biosimilar Introduction: A Nationwide Australian Real-World Study.

Chin Hang Yiu, Bella D Ianni, Richard O Day

|Jun 25, 2025

Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence.

Chin Hang Yiu, Grace Tsz Yan Yau, Zoi Hei Wong

|Jun 05, 2025

Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.

Ramya Padmavathy Radha Krishnan, Monika Dzidowska, Danni Zheng

|May 26, 2025

Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.

Chin Hang Yiu, Chung Hin Or, Khalid Almutairi

Pageof 4

Frequent Collaborators

Nick A Buckley

Christine Y Lu

Richard O Day

Chin Hang Yiu

Fahim Mohamed

Firouzeh Noghrehchi

Andrew H Dawson

Jennifer E Merrill

Benjamin C Riordan

Rose Marie Ward

Frequent Collaborators

Nick A Buckley

Christine Y Lu

Richard O Day

Chin Hang Yiu